A Phase 3 interventional study of Budesonide granules 9 mg and Placebo granules in Incomplete Microscopic Colitis, sponsored by Dr. Falk Pharma GmbH. Completed at 2 sites in 2 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2020-07-22.
Sponsored by Dr. Falk Pharma GmbH · Phase 3, Interventional, and Treatment
The purpose of this study is to demonstrate the efficacy of budesonide for the treatment of active incomplete microscopic colitis.
Exclusion Criteria:
Budesonide granules 9 mg
Drug: Budesonide granules 9 mg
Placebo granules
Drug: Placebo granules
per day
per day
Rate of clinical remission
Time frame: 8 weeks
Rate of clinical remission
Time frame: 2 weeks
Rate of clinical remission
Time frame: 6 weeks
Time to remission
Time frame: 8 weeks
Number of formed/soft/watery stools per week
Time frame: 8 weeks
Number of days with abdominal pain
Time frame: 8 weeks
Number of days with urgency
Time frame: 8 weeks
Rate of histological remission
Time frame: 8 weeks
Physician's global assessment at final visit
Time frame: 8 weeks
Quality of life
Time frame: 8 weeks
This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Dr. Falk Pharma GmbH